+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Thromboembolism Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

  • ID: 4830108
  • Drug Pipelines
  • August 2019
  • Region: Global
  • 73 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Arrowhead Pharmaceuticals
  • Bayer AG
  • Daiichi Sankyo Co Ltd
  • Espero BioPharma Inc
  • EVAS Therapeutics LLC
  • GC Pharma
  • MORE
High levels of pipeline activity are being observed in Thromboembolism treatment during 2019. Clinical development activities are being undertaken by more than 15 companies including Arrowhead Pharmaceuticals, Bayer AG, China Biologic Products Holdings Inc, Daiichi Sankyo Co Ltd, Espero BioPharma Inc and others.

A Significant contribution to the Thromboembolism pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Thromboembolism pipeline included 17 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Thromboembolism condition and increased access to investments is encouraging growth of Thromboembolism drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Thromboembolism drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Thromboembolism therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Thromboembolism pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Thromboembolism. Further, orphan drug status, fast track designation, grants awarded and other special status for Thromboembolism pipeline compounds are also included.

This study was produced independently by the publisher from their proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Thromboembolism pipeline and formulate effective research and development strategies.

Research Methodology

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Thromboembolism Pipeline candidates
  • Pre-clinical Phase: Discovery, research, pre-clinical
  • Early Phase: Phase 1 and Phase 2 Thromboembolism drugs
  • Late phase: Phase 3 and in-approval Thromboembolism drugs
Companies involved in the Pipeline
  • Company overview
  • Snapshot
  • Thromboembolism therapeutic treatment activities
Details for each Thromboembolism drug candidate
  • Snapshot
  • Drug Name
  • Alternative Names
  • Company
  • Originator
  • Phase
  • Molecule Type
  • Orphan Drug Status
  • Drug Overview
  • Mechanism of Action
  • Current Status
  • Trial Details
Other details
  • Pre-clinical trials for each drug candidate
  • Clinical trials for each drug candidate
Recent Thromboembolism therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Arrowhead Pharmaceuticals
  • Bayer AG
  • Daiichi Sankyo Co Ltd
  • Espero BioPharma Inc
  • EVAS Therapeutics LLC
  • GC Pharma
  • MORE
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Thromboembolism- Disease Overview
2.2 Thromboembolism- Pipeline Snapshot
2.3 Thromboembolism- Pipeline Drugs by Phase
2.4 Thromboembolism- Pipeline Drugs by Company
2.5 Thromboembolism- Pipeline Drugs by Mechanism of Action

3 Company wise Pipeline Analysis
3.1 Arrowhead Pharmaceuticals Thromboembolism Drug Pipeline, H2- 2019
3.2 Bayer AG Thromboembolism Drug Pipeline, H2- 2019
3.3 China Biologic Products Holdings Inc Thromboembolism Drug Pipeline, H2- 2019
3.4 Daiichi Sankyo Co Ltd Thromboembolism Drug Pipeline, H2- 2019
3.5 Espero BioPharma Inc Thromboembolism Drug Pipeline, H2- 2019
3.6 EVAS Therapeutics LLC Thromboembolism Drug Pipeline, H2- 2019
3.7 GC Pharma Thromboembolism Drug Pipeline, H2- 2019
3.8 Ionis Pharmaceuticals Inc Thromboembolism Drug Pipeline, H2- 2019
3.9 Janssen Pharmaceuticals Inc Thromboembolism Drug Pipeline, H2- 2019
3.10 Laboratorios Farmaceuticos Rovi SA Thromboembolism Drug Pipeline, H2- 2019
3.11 Ono Pharmaceutical Co Ltd Thromboembolism Drug Pipeline, H2- 2019
3.12 Portola Pharmaceuticals Inc Thromboembolism Drug Pipeline, H2- 2019
3.13 Tasly Pharmaceutical Group Co Ltd Thromboembolism Drug Pipeline, H2- 2019
3.14 TeaRx Ltd Thromboembolism Drug Pipeline, H2- 2019
3.15 Tetherex Pharmaceuticals Corp Thromboembolism Drug Pipeline, H2- 2019
3.16 Translational Sciences Inc Thromboembolism Drug Pipeline, H2- 2019
3.17 Verseon Corp Thromboembolism Drug Pipeline, H2- 2019

4 Phase 1 Pipeline Drug Details
4.1 Thromboembolism- Phase 1 Drug Details
4.2 Thromboembolism- Phase 1 Drug Overview
4.3 Thromboembolism- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details

5 Phase 2 Pipeline Drug Details
5.1 Thromboembolism- Phase 2 Drug Details
5.2 Thromboembolism- Phase 2 Drug Overview
5.3 Thromboembolism- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details

6 Phase 3 Pipeline Drug Details
6.1 Thromboembolism- Phase 3 Drug Details
6.2 Thromboembolism- Phase 3 Drug Overview
6.3 Thromboembolism- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details

7 Pre-clinical Phase Pipeline Drug Details
7.1 Thromboembolism- Pre-clinical Phase Drug Details
7.2 Thromboembolism- Pre-clinical Phase Drug Overview
7.3 Thromboembolism- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details

8 Recent News and Developments

9 Appendix
9.1 About the Publisher
9.2 Sources and Research Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Arrowhead Pharmaceuticals
  • Bayer AG
  • China Biologic Products Holdings Inc
  • Daiichi Sankyo Co Ltd
  • Espero BioPharma Inc
  • EVAS Therapeutics LLC
  • GC Pharma
  • Ionis Pharmaceuticals Inc
  • Janssen Pharmaceuticals Inc
  • Laboratorios Farmaceuticos Rovi SA
  • Ono Pharmaceutical Co Ltd
  • Portola Pharmaceuticals Inc
  • Tasly Pharmaceutical Group Co Ltd
  • TeaRx Ltd
  • Tetherex Pharmaceuticals Corp
  • Translational Sciences Inc
  • Verseon Corp
Note: Product cover images may vary from those shown
Adroll
adroll